Autoantibody Signature for the Early Detection of Ovarian Cancer
Ovarian cancer is the ninth most common cancer among women and is the fifth leading cause of cancer-related mortality among women in the U.S. When ovarian cancer is diagnosed early, the five year survival rate is about 94%; however, the majority of patients are diagnosed with advanced disease. CA 125 (cancer antigen 125) has been identified as a biomarker for ovarian cancer, though the utility of CA 125 as a screening test is limited by a low sensitivity of 50% for early stage disease at 99% specificity. To date, there are no screening biomarkers recommended for the general population in detecting ovarian cancer.
Researchers at the Biodesign Institute of Arizona State University and collaborators have identified twelve antigens as potential biomarkers for early stage detection of ovarian cancer. The biomarkers were selected out of 5177 candidate tumor antigens in a sequential screening study and show sensitivities ranging from 13-22% at >93% specificity. These twelve biomarkers can be utilized on an array or other substrate as a diagnostic test in which patient sera is tested for ovarian cancer autoantibodies.
These biomarkers may be critical components of diagnostic tests and personalized therapeutics for ovarian cancer.
- Diagnostic tests to detect ovarian cancers
- Monitoring of ovarian cancer treatment
- Components of personalized ovarian cancer therapy
Benefits and Advantages
- Potentially the first screening biomarkers for ovarian cancer
- High specificity